Paul Inclan1, Travis S CreveCoeur2, Shay Bess3, Jeffrey L Gum4, Breton G Line3, Lawrence G Lenke5, Michael P Kelly6. 1. Department of Orthopedic Surgery, Washington University School of Medicine, 660 Euclid Avenue, St. Louis, MO, 63110, USA. 2. Department of Neurological Surgery, Neurological Institute of New York, Columbia University College of Physicians and Surgeons, New York, NY, USA. 3. Denver International Spine Center, Presbyterian St. Luke's/Rocky Mountain Hospital for Children, Denver, CO, USA. 4. Norton Leatherman Spine Center, Louisville, KY, USA. 5. Department of Orthopaedic Surgery, Columbia University College of Physicians and Surgeons, The Spine Hospital at New York Presbyterian, New York, NY, USA. 6. Rady Children's Hospital, University of California, San Diego, San Diego, CA, USA. mkelly5@rchsd.org.
Abstract
PURPOSE: To validate the Scoliosis Research Society-22r (SRS-22r) question 11 (Q11) response as a measure to assess and quantify opioid consumption. METHODS: A post hoc analysis of a prospective study regarding opioid use during ASD surgery was performed. Data were collected at enrollment and 2-year follow-up including the SRS-22r and a standardized data collection form (CRF) for self-reported opioid consumption. Responses to Q11 of the SS-22r were compared with responses to the opioid consumption CRF (as measured by morphine equivalent dose (MED)). Inter-rater agreement was calculated. Sensitivity and specificity for the Q11 (+) responses were calculated using MED reports as the "true" value. RESULTS: Cohen's kappa indicated almost perfect agreement between the MED CRF and Q11 (k = 0.878, p < 0.001). Mean daily MED consumption for patients reporting "Daily Narcotic" use was 62.0 (Median: 38.7, SD 87.5) mg; for patients reporting "Narcotics weekly or less", mean daily MED consumption was 21.6 (15.0, 29.0) mg. The positive Q11 responses were 96% sensitive and 92% specific for opioid users. CONCLUSION: SRS-22r Q11 exhibits almost perfect agreement with an independent questionnaire designed to assess opioid consumption in this cohort. "Daily narcotic" users report nearly three times the mean daily MED of "Weekly or less" users (62.0 ± 87.5 mg vs 21.6 ± 29 mg, p = 0.037). Q11 exhibited excellent sensitivity and specificity for determining opioid users and non-users. Given the need for opioid research in ASD, Q11 may be useful to use existing registries and observational cohorts to design more definitive studies regarding opioid consumption. LEVEL OF EVIDENCE: III.
PURPOSE: To validate the Scoliosis Research Society-22r (SRS-22r) question 11 (Q11) response as a measure to assess and quantify opioid consumption. METHODS: A post hoc analysis of a prospective study regarding opioid use during ASD surgery was performed. Data were collected at enrollment and 2-year follow-up including the SRS-22r and a standardized data collection form (CRF) for self-reported opioid consumption. Responses to Q11 of the SS-22r were compared with responses to the opioid consumption CRF (as measured by morphine equivalent dose (MED)). Inter-rater agreement was calculated. Sensitivity and specificity for the Q11 (+) responses were calculated using MED reports as the "true" value. RESULTS: Cohen's kappa indicated almost perfect agreement between the MED CRF and Q11 (k = 0.878, p < 0.001). Mean daily MED consumption for patients reporting "Daily Narcotic" use was 62.0 (Median: 38.7, SD 87.5) mg; for patients reporting "Narcotics weekly or less", mean daily MED consumption was 21.6 (15.0, 29.0) mg. The positive Q11 responses were 96% sensitive and 92% specific for opioid users. CONCLUSION: SRS-22r Q11 exhibits almost perfect agreement with an independent questionnaire designed to assess opioid consumption in this cohort. "Daily narcotic" users report nearly three times the mean daily MED of "Weekly or less" users (62.0 ± 87.5 mg vs 21.6 ± 29 mg, p = 0.037). Q11 exhibited excellent sensitivity and specificity for determining opioid users and non-users. Given the need for opioid research in ASD, Q11 may be useful to use existing registries and observational cohorts to design more definitive studies regarding opioid consumption. LEVEL OF EVIDENCE: III.
Authors: Chad M Brummett; Jennifer F Waljee; Jenna Goesling; Stephanie Moser; Paul Lin; Michael J Englesbe; Amy S B Bohnert; Sachin Kheterpal; Brahmajee K Nallamothu Journal: JAMA Surg Date: 2017-06-21 Impact factor: 14.766
Authors: Michael P Kelly; Jon D Lurie; Elizabeth L Yanik; Christopher I Shaffrey; Christine R Baldus; Oheneba Boachie-Adjei; Jacob M Buchowski; Leah Y Carreon; Charles H Crawford; Charles Edwards; Thomas J Errico; Steven D Glassman; Munish C Gupta; Lawrence G Lenke; Stephen J Lewis; Han Jo Kim; Tyler Koski; Stefan Parent; Frank J Schwab; Justin S Smith; Lukas P Zebala; Keith H Bridwell Journal: J Bone Joint Surg Am Date: 2019-02-20 Impact factor: 5.284
Authors: Lauren K Dunn; Marcel E Durieux; Lucas G Fernández; Siny Tsang; Emily E Smith-Straesser; Hasan F Jhaveri; Shauna P Spanos; Matthew R Thames; Christopher D Spencer; Aaron Lloyd; Russell Stuart; Fan Ye; Jacob P Bray; Edward C Nemergut; Bhiken I Naik Journal: J Neurosurg Spine Date: 2017-11-10
Authors: Lauren K Dunn; Sandeep Yerra; Shenghao Fang; Mark F Hanak; Maren K Leibowitz; Siny Tsang; Marcel E Durieux; Edward C Nemergut; Bhiken I Naik Journal: Anesth Analg Date: 2018-07 Impact factor: 5.108
Authors: Sheyan J Armaghani; Dennis S Lee; Jesse E Bible; David N Shau; Harrison Kay; Chi Zhang; Matthew J McGirt; Clinton J Devin Journal: Clin Spine Surg Date: 2016-03 Impact factor: 1.876
Authors: Andrew J Schoenfeld; Kenneth Nwosu; Wei Jiang; Allan L Yau; Muhammad Ali Chaudhary; Rebecca E Scully; Tracey Koehlmoos; James D Kang; Adil H Haider Journal: J Bone Joint Surg Am Date: 2017-08-02 Impact factor: 5.284
Authors: Qiushi Chen; Marc R Larochelle; Davis T Weaver; Anna P Lietz; Peter P Mueller; Sarah Mercaldo; Sarah E Wakeman; Kenneth A Freedberg; Tiana J Raphel; Amy B Knudsen; Pari V Pandharipande; Jagpreet Chhatwal Journal: JAMA Netw Open Date: 2019-02-01